Antithrombin, heparin, and heparan sulfate
- 1 May 2002
- journal article
- review article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 30 (Supplement) , S325-S331
- https://doi.org/10.1097/00003246-200205001-00024
Abstract
To review the experimental and clinical evidence that antithrombin has multiple mechanisms for both its anticoagulant and anti-inflammatory properties. The interaction between antithrombin and specific polysulfated, acidic oligosaccharide moieties found on heparin and related proteoglycan molecules within the circulation and on endothelial surfaces will also be examined. Review of the literature relating to antithrombin published during the past 25 yrs. Antithrombin is the most abundant endogenous anticoagulant circulating in human plasma. This serine protease inhibitor participates in the regulation of clotting in both physiologic and pathologic states. Reduced antithrombin activity in the early phases of sepsis contributes to a procoagulant state with excess activation of the innate immune response. Antithrombin binds to specific pentasaccharides expressed on heparin, glycosaminoglycans, and related proteoglycans within the circulation and along endothelial surfaces. The functions of neutrophils, monocytes, and endothelial cells are altered as a result of their interaction with antithrombin. These effects are mediated by the enzyme inhibitory action of antithrombin and its ability to function as a ligand for antithrombin receptors on cell surfaces. In addition, antithrombin exerts anti-inflammatory properties by both prostacyclin-dependent and prostacyclin-independent actions; heparin interferes with these anti-inflammatory properties. The role of antithrombin in sepsis, its therapeutic utility in severe sepsis, and its combination with heparin remain the subject of considerable debate. The results of a recent phase 3 clinical trials with high-dose antithrombin in sepsis suggested a beneficial effect in patients who did not concomitantly receive heparin, thereby generating new challenges in the understanding of interactions between antithrombin and heparin or heparin-like proteoglycans. Antithrombin has complex interactions with host coagulopathic and systemic inflammatory responses under physiologic conditions and in sepsis. The impact of these interactions in critically ill patients and the therapeutic implications of administration of antithrombin, and various doses and types of heparin in such patients, need further clarification.Keywords
This publication has 66 references indexed in Scilit:
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001
- Phylogenetic and functional relationships between coagulation and the innate immune responseCritical Care Medicine, 2000
- Disseminated Intravascular CoagulationNew England Journal of Medicine, 1999
- Antithrombin III in Animal Models of Sepsis and Organ FailureSeminars in Thrombosis and Hemostasis, 1998
- Derangements of Coagulation and Fibrinolysis in Critically III Patients with Sepsis and Septic ShockSeminars in Thrombosis and Hemostasis, 1998
- Pathogenesis of focal and random hepatocellular necrosis in endotoxemia: microscopic observation in vivoLiver International, 1996
- Time Course of Hemostatic Abnormalities in Sepsis and its Relation to OutcomeChest, 1993
- ANTITHROMBIN-III TRANSFUSION IN DISSEMINATED INTRAVASCULAR COAGULATIONThe Lancet, 1978
- Heparin therapy in bacterial septicemiaThe Journal of Pediatrics, 1977
- THE NORMAL ANTITHROMBIN OF THE BLOOD AND ITS RELATION TO HEPARINAmerican Journal of Physiology-Legacy Content, 1938